

Prism Medico & Pharmacy Limited

CIN: L51109PB2002PLC047444

D-118, INDUSTRIAL AREA,
PHASE VII, MOHALI-160055
Telephone no – 0172-5020762
Email Id – investorgrievancewmcl@gmail.com

Date: 04/08/2018

To, Department of Corporate Services, BSE Limited P.J. Towers, Dalal Street, Mumbai – 400 001. Scip Code: 512217	To, Listing Department, Metropolitan Stock Exchange of India Ltd. (MSE) Vibgyor Towers, 4th floor, Plot No C 62, G - Block, Opp. Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai – 400 098, India. ISIN : INE730E01016
--	--

Subject: Intimation of Board meeting and closer of trading Window

Dear Sir/Madam

We hereby inform you that the meeting of Board of Directors of the Company will be held on **Tuesday, 14th August, 2018 at 11.00 a.m.** at **D-118, Industrial area, Phase VII, Mohali-160059** to consider and discuss the following items:

1. To inter-alia consider and take on record the Un-audited Financial Results of the Company for the quarter ended **June 30, 2018**.
2. Further, in terms of the Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, framed pursuant to the Securities and Exchange Board of India (Prohibiting of Insider Trading) Regulations, 2015, **the Trading Window for dealing in the Securities of the Company shall remain close for all "Specified Persons" from business hours of August 04, 2018 to ending 48 hours when the information is made public on August 14, 2018 (both days inclusive)**. Accordingly, all the Directors, connected persons and designated Employees of the Company have been intimated not to enter into any transactions involving the securities or deal in securities of the Company during the aforesaid period of closure of Trading Window.
3. To consider and final the date of Annual General Meeting to be held.

Prism Medico & Pharmacy Limited

CIN: L51109PB2002PLC047444

D-118, INDUSTRIAL AREA,
PHASE VII, MOHALI-160055
Telephone no – 0172-5020762
Email Id – investorgrievancewmcl@gmail.com

4. To consider issue and allot, subject to the approval of Shareholders, equity shares on preferential basis as per SEBI (ICDR) Regulations and also decide the matters consequential thereto.
5. To consider increase of Authorized Share Capital from 10,00,00,000 to 20,00,00,000, subject to the approval of Shareholders
6. To consider change in main object of the Company.
7. To consider change in name of the Company.
8. Any other matter with the permission of the Chair.


Kindly take the same on your record.

Thanking You,

Yours Truly,

For **PRISM MEDICO & PHARMACY LIMITED**

For PRISM MEDICOS AND PHARMACY LIMITED



Gursimran Singh

DIRECTOR

DIN: 02209675

Authorised Signatory